ABL-MYC is a recombinant retrovirus that constitutively expresses v-abl and c-myc oncogenes. When used to infect antigen-activated splenocytes, this retroviral system rapidly induces antigen-specific plasmacytomas (5, 6). ABL-MYC targets antigen-stimulated (Ag-stimulated) B-cells for transformation. We have demonstrated that this is a useful method for the generation of monoclonal antibodies secreted from the plasmacytoma.

Read more about the advantages to our system.

We have the exclusive license to the ABL-MYC patents.

Read more about the ABL-MYC system; see ABL-MYC references.